Immunotherapy Drugs Market Global Industry Analysis

ImmunotherapyDefinition and Origins of Immunotherapy

Immunotherapy is a treatment procedure that is designed to rein in the human body’s immune system to combat infections or disease. Immunotherapy helps in producing an immune response to diseases such as cancer by harnessing the immune system. Immunotherapy is also known as biological therapy as it often uses the substances referred to as biological response modifiers (BRMs). The human body usually produces small amounts of these BRMs in response to infection or disease. However, in laboratory large amounts of these BRMs can be generated to provide a therapy for cancer, arthritis, rheumatoid and other illnesses.

Download free sample report :

William B. Coley, MD is known as the Father of Immunotherapy having attempted in harnessing the immune system for treatment of cancer during the late 19th century. The immunotherapy drugs such as checkpoint inhibitors that release the brakes on the immune system and cell-based therapies using genetically engineered immune cells are showing good results in some patients thereby effectively curing them of their cancer.

Global Immunotherapy Drugs Market – An overview

The global immunotherapy drugs market is estimated to be worth U.S. $68.4 billion in 2016, which is projected to reach U.S. $ 112.69 billion by the end of 2021 with a significant CAGR of 10.5%. Within the cancer therapeutics, immunotherapy drugs have gained global acceptance because they are targeted drugs that target only cancer cells.

Inquire before buying :

As per a reputed immunotherapy drugs market research report, the cancer immunotherapy space will emerge as a significant revenue generator that may exceed $80 billion for the biopharmaceutical industry by 2020. Over the next ten years, immunotherapy drugs market growth is expected to rise with immunotherapy remaining the backbone of cancer treatments in 60% of cancer types.  The rising prevalence of autoimmune cancer leading to technological innovations had helped in developing immunotherapy drugs that are more effective than the prevailing drugs.

The power of immunotherapy drugs to treat cancer including the very advanced and metastatic diseases has been well documented through several recent clinical trials that resulted in the production of immunotherapy drugs such as Ipilimumab (Yervov) which is now the first line treatment for patients with metastatic melanoma – a type of cancer that is largely resistant to standard chemotherapy.

A significant production of Antibody Drug Conjugates (ADCs), checkpoint inhibitors, cancer vaccines and PD-1/PD-L1 agents has helped in the expansion of the global immunotherapy drugs market reach with a vertical growth in this area over the next ten years. More than fifteen companies are in the process of developing 30 different ADCs that target both hematologic malignancies and solid tumors. The ADCs are gaining increased attention from both large and small pharmaceutical companies due to their efficiency in the treatment of cancer.

Segmentation of global immunotherapy drugs market – A preview

The global immunotherapy drug market is segmented based on the factors as shown in a tabular format herein below-

Drug Type Therapy End User Region
Monoclonal antibodies Targeted Cancer Therapies Hospitals North America
Interferons Hormone Therapies Clinics Europe
Interleukins Immunotherapy Others Asia-Pacific
Vaccines and Checkpoint Inhibitors Chemotherapy   Latin America
  Inflammatory Diseases   Middle East
  Infectious Diseases   Africa

Table: 1 – Segmentation of Global Immunotherapy Drugs Market

The cancer segment accounts for the largest share and is the fastest growing segment in the global immunotherapy market. Factors such as the first line preference for immunotherapy for the treatment of cancer are leading to a growing demand for the immunotherapy drugs. In addition, the emergence of biosimilars, higher efficiency of the immunotherapy drugs with lower side effects and research and development activities for the development of new immunotherapy drugs is driving the overall immunotherapy drugs market growth.

Based on geographical segmentation, North America accounts for the largest share of the immunotherapy drug market in 2016 with oncology spending remaining concentrated to America and European markets that account for 65% of the global immunotherapy drug market.  Asia-Pacific regions such as India, Japan, and China are emerging as the new growth areas for the global immunotherapy drug market. The key players that are involved in the production of the immunotherapy drugs include-

  • Amgen
  • Merck
  • Roche
  • Eli Lily
  • Novartis
  • Seattle Genetics

The above-mentioned key players are working to develop novel combinations of drugs of immune/targeted therapies.

Visit here for more reports:

Share this post:

Recent Posts

Leave a Comment

1 + 7 =